capecitabine has been researched along with dasatinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Curtiss, FR | 1 |
| Atzori, F; Cortes, J; Geese, WJ; Gradishar, WJ; Rybicki, A; Somlo, G; Specht, JM; Strauss, LC; Sy, O; Vahdat, LT | 1 |
| Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY | 1 |
1 review(s) available for capecitabine and dasatinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for capecitabine and dasatinib
| Article | Year |
|---|---|
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A | 2014 |
1 other study(ies) available for capecitabine and dasatinib
| Article | Year |
|---|---|
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |